In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties.<\/p>\n
This information has been prepared by the notifying parties, who are solely responsible for it. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.<\/p>\n
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented.<\/p>\n
Names of the companies and individuals involved:<\/strong><\/p>\n Nature of the operation<\/strong><\/p>\n Economic sector concerned:<\/strong><\/p>\n Deadline for interested third parties to submit their observations:<\/strong><\/p>\n NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES<\/strong><\/p>\n The Competition Council has received notification of an economic concentration project concerning the exclusive control acquisition by the company \u201cCooper Pharma SA\u201d of the manufacturing and marketing of the following pharmaceutical products held by the company \u201cSanofi Aventis Maroc\u201d: Relaxol, Coltramyl, Thiobactin, and Paroxetine win, in Morocco, Tunisia, and in certain sub-Saharan African countries.<\/p>\n \u201cCooper Pharma SA\u201d is a Moroccan joint-stock company, active in research and development, production, and marketing of health products.<\/p>\n \u201cSanofi Aventis Maroc SA\u201d, a subsidiary of the \u201cSanofi\u201d group, is a Moroccan joint-stock company operating in research, development, manufacturing, and marketing of health solutions.<\/p>\n Done in Rabat on December 19, 2024<\/p>\n","protected":false},"excerpt":{"rendered":" In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 issued for its implementation, as amended and supplemented, the Competition Council makes available to the public the \u201csummary of the operation\u201d below, containing the information provided by the parties. This information has been prepared by the notifying parties, who are solely responsible for it. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation. The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 issued for the implementation of Law No. 104-12 on freedom of prices and competition, as amended and supplemented. Names of the companies and individuals involved: The acquirer: \u201cCooper Pharma SA\u201d; The target: the assets of the company \u201cSanofi Aventis Maroc SA\u201d related to the manufacturing and marketing of the following pharmaceutical products: Relaxol, Coltramyl, Thiobactin, and Paroxetine win. Nature of the operation Exclusive control acquisition. Economic sector concerned: Pharmaceutical industry sector. Deadline for interested third parties to submit their observations: 10 days from the date of publication of this press release, i.e., January 2, 2025. NON-CONFIDENTIAL SUMMARY OF THE OPERATION PROVIDED BY THE PARTIES The Competition Council has received notification of an economic concentration project concerning the exclusive control acquisition by the company \u201cCooper Pharma SA\u201d of the manufacturing and marketing of the following pharmaceutical products held by the company \u201cSanofi Aventis Maroc\u201d: Relaxol, Coltramyl, Thiobactin, and Paroxetine win, in Morocco, Tunisia, and in certain sub-Saharan African countries. \u201cCooper Pharma SA\u201d is a Moroccan joint-stock company, active in research and development, production, and marketing of health products. \u201cSanofi Aventis Maroc SA\u201d, a subsidiary of the \u201cSanofi\u201d group, is a Moroccan joint-stock company operating in research, development, manufacturing, and marketing of health solutions. Done in Rabat on December 19, 2024<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[352],"tags":[],"class_list":["post-40217","post","type-post","status-publish","format-standard","hentry","category-press-releases"],"acf":[],"yoast_head":"\n\n
\n
\n
\n